Many doctors are too biased by their "standard of care" dogma. The clinical evidence from a few years of Acoramidis trials versus Tafadamis trials doesn't support the idea that you should continue taking Vyndamax (Tafadamis) and not switch to Attruby (Acoramidis). It is far more effective as a TTR stabilizer.

As for me, I will gladly give up my stabilizer drug in favor of Amvuttra (Vutrisiran), a knockdown or silencer drug.

My understanding of the new FDA-approved drug, Acoramidis, is that it was highly effective in trials, 90 percent, in stabilizing and preventing increase of rogue protein buildup in organs. That said, if you are taking Vyndamax and it appears to be working, your amyloidosis doctor may not want to change. Bottom line: ask your doc whether your condition might improve or be stabilized by Acoramidis. Your doc’s opinions are, of course, the most crucial in any consideration of your treatments.

I’ve been taking Vyndamax almost four years, and my doc says I’m in far better health than when diagnosed.
Ron Cohen (wild type)

That is a great plan! What is your NYHA Heart Failure classification I,, II or III

I am taking Attruby and will be adding Amvuttra next week .
Taking both together